Xgeva Rejection Shows What’s Needed For Non-Metastatic CRPC Approvals

As expected, FDA rejected the new indication for Amgen’s bone drug Xgeva in prevention of bone metastases. But the door is still open for other therapies for castration resistant prostate cancer to target earlier stages of disease.